List of investigational obsessive–compulsive disorder drugs

This is a list of investigational obsessive–compulsive disorder drugs, or drugs that are currently under development for clinical use in the treatment of obsessive–compulsive disorder (OCD) but are not yet approved. Chemical/generic names are listed first, with developmental code names, synonyms, and brand names in parentheses.

Actively under development

 * Immunoglobulin (immune globulin 10%, 10% high purity immunoglobulin, 10% IVIG, NewGam, Newnorm, Octagam 10%, Octagam, Panzyga) – immunoglobulin / immunostimulant
 * Troriluzole (BHV-4157, BHV-4157a, FC-4157; trigriluzole) – prodrug of riluzole / glutamate modulator

Preclinical development

 * Cannabis extracts (various) – cannabinoid receptor modulators

No development reported

 * 4'-Fluorocannabidiol (4'-F-CBD; fluorinated cannabidiol; HUF-101, HUF-102, HUF-103) – cannabinoid receptor modulator, other actions
 * AbbVie/Rugen research programme – unspecified mechanism of action
 * Agomelatine (Alodil, Melitor, Thymanax, Valdoxan, Vestin; AGO-178, AGO178C, S-20098, S-20098-F55) – serotonin 5-HT2C receptor antagonist and melatonin receptor agonist
 * CR-5542 – orexin receptor antagonist
 * Dual SSRIs and serotonin 5-HT1A receptor agonists (SSA-426, WAY-163426, WAY-211612, WAY-253752, WAY-426)
 * Risperidone (Risperdal, Risperdal Consta, Risperdal Depot; JNJ-410397-AAA, R-64766, R064766) – atypical antipsychotic / monoamine receptor modulator
 * Secretin (SecreFlo; INN-329, RG-1068) – hormone/diagnostic agent
 * Sosei Heptares research programme – various mechanisms of action

Development discontinued

 * Bitopertin (R-1678, RG-6718, RG1678, RO-4917838) – glycine GlyT1 inhibitors / glycine reuptake inhibitor
 * Cycloserine ( D -cycloserine; TIK-101) – glutamate NMDA receptor partial agonist
 * Elzasonan (CP-448187, CP-448187-01) – serotonin 5-HT1B and 5-HT1D receptor antagonist
 * F-14258 – serotonin 5-HT1B and 5-HT1D receptor antagonist
 * Fluoxetine/naltrexone (OREX-004) – selective serotonin reuptake inhibitor and opioid receptor antagonist
 * Mavoglurant (AFQ-056) – glutamate mGlu5 receptor antagonist
 * NPL-2003 – glutamate modulator
 * Ondansetron (Setrodon; TO-2061) – serotonin 5-HT3 receptor antagonist
 * RO-600175 – serotonin 5-HT2C receptor agonist
 * Roxindole (EMD-49980) – dopamine receptor agonist, serotonin receptor modulator, adrenergic receptor modulator, and serotonin reuptake inhibitor
 * SB-200646 (SB-200646A) – serotonin 5-HT2B and 5-HT2C receptor antagonist

Formal development never or not yet started

 * 5-HT6 receptor agonists (e.g., WAY-181187, WAY-208466)
 * Antiandrogens (e.g., flutamide, cyproterone acetate, triptorelin)
 * Cannabinoids (e.g., nabilone, tetrahydrocannabinol (THC)/cannabis) – cannabinoid receptor modulators
 * NMDA receptor modulators (e.g., ketamine, memantine, nitrous oxide, rapastinel)
 * Nonsteroidal anti-inflammatory drugs (NSAIDs) (e.g., celecoxib, naproxen) – cyclooxygenase inhibitors
 * Rituximab (Rituxan) – monoclonal antibody against CD20
 * Serotonergic psychedelics (e.g., psilocybin/psilocybin mushrooms, lysergic acid diethylamide (LSD)) – serotonin receptor modulators
 * Tolcapone (Tasmar) – catechol-O-methyltransferase inhibitor

Approved drugs

 * Clomipramine (Anafranil) – tricyclic antidepressant / monoamine reuptake inhibitor and receptor modulator
 * Escitalopram (S-citalopram; Cipralex, Entact, Lexapro, Seroplex, Sipralex, Sipralexa; LU-26054; MLD-55) – selective serotonin reuptake inhibitor
 * Fluoxetine (Prozac, Prozac Weekly, Reneuron, Sarafem; LY-110140) – selective serotonin reuptake inhibitor
 * Fluvoxamine (Depromel, Luvox, Luvox CR; SME-3110) – selective serotonin reuptake inhibitor and sigma-1 receptor agonist
 * Paroxetine (Aropax, Deroxat, Divarius, Dropax, Dropaxin, Frosinor, Motivan, Paxil, Paxil CR, Serestill, Seroxat, Tagonis; BRL-29060, BRL-29060A, FG-7051, NNC-207051, SI-211103) – selective serotonin reuptake inhibitor
 * Sertraline (Aremis, Besitran, Gladem, J Zoloft, Lustral, Serad, Serlain, Tatig, Zoloft; CP-51974, CP-51974-01) – selective serotonin reuptake inhibitor

Off-label drugs

 * Atypical antipsychotics (e.g., aripiprazole, olanzapine, quetiapine, risperidone) – monoamine receptor modulators